Literature DB >> 25929733

The role of complement in C3 glomerulopathy.

Peter F Zipfel1, Christine Skerka2, Qian Chen2, Thorsten Wiech3, Tim Goodship4, Sally Johnson4, Veronique Fremeaux-Bacchi5, Clara Nester6, Santiago Rodríguez de Córdoba7, Marina Noris8, Matthew Pickering9, Richard Smith6.   

Abstract

C3 glomerulopathy describes a spectrum of disorders with glomerular pathology associated with C3 cleavage product deposition and with defective complement action and regulation (Fakhouri et al., 2010; Sethi et al., 2012b). Kidney biopsies from these patients show glomerular accumulation or deposition of C3 cleavage fragments, but no or minor deposition of immunoglobulins (Appel et al., 2005; D'Agati and Bomback, 2012; Servais et al., 2007; Sethi and Fervenza, 2011). At present the current situation asks for a better definition of the underlining disease mechanisms, for precise biomarkers, and for a treatment for this disease. The complement system is a self activating and propelling enzymatic cascade type system in which inactive, soluble plasma components are activated spontaneously and lead into an amplification loop (Zipfel and Skerka, 2009). Activation of the alternative pathway is spontaneous, occurs by default, and cascade progression leads to amplification by complement activators. The system however is self-controlled by multiple regulators and inhibitors, like Factor H that control cascade progression in fluid phase and on surfaces. The activated complement system generates a series of potent effector components and activation products, which damage foreign-, as well as modified self cells, recruit innate immune cells to the site of action, coordinate inflammation and the response of the adaptive immune system in form of B cells and T lymphocytes (Kohl, 2006; Medzhitov and Janeway, 2002; Ogden and Elkon, 2006; Carroll, 2004; Kemper and Atkinson, 2007; Morgan, 1999; Muller-Eberhard, 1986; Ricklin et al., 2010). Complement controls homeostasis and multiple reactions in the vertebrate organism including defense against microbial infections (Diaz-Guillen et al., 1999; Mastellos and Lambris, 2002; Nordahl et al., 2004; Ricklin et al., 2010). In consequence defective control of the spontaneous self amplifying cascade or regulation is associated with numerous human disorders (Ricklin and Lambris, 2007; Skerka and Zipfel, 2008; Zipfel et al., 2006). Understanding the exact action and regulation of this sophisticated homeotic cascade system is relevant to understand disease pathology of various complement associated human disorders. Furthermore this knowledge is relevant for a better diagnosis and appropriate therapy. At present diagnosis of C3 glomerulopathy is primarily based on the kidney biopsy, and histological, immmunohistological and electron microscopical evaluation (D'Agati and Bomback, 2012; Fakhouri et al., 2010; Medjeral-Thomas et al., 2014a,b; Sethi et al., 2012b). The challenge is to define the actual cause of the diverse glomerular changes or damages, to define how C3 deposition results in the reported glomerular changes, the location of the cell damage and the formation of deposits.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  C3 nephritic factor; Complement C3 glomerulopathy; Dense deposit diseases; MPGN membranoproliferative

Mesh:

Substances:

Year:  2015        PMID: 25929733     DOI: 10.1016/j.molimm.2015.03.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  44 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 2.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

Review 3.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

4.  Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

Authors:  Maria Chiara Marinozzi; Lubka T Roumenina; Sophie Chauvet; Alexandre Hertig; Dominique Bertrand; Jérome Olagne; Marie Frimat; Tim Ulinski; Georges Deschênes; Stephane Burtey; Michel Delahousse; Bruno Moulin; Christophe Legendre; Véronique Frémeaux-Bacchi; Moglie Le Quintrec
Journal:  J Am Soc Nephrol       Date:  2017-01-17       Impact factor: 10.121

Review 5.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

6.  C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

Authors:  Yuzhou Zhang; Nicole C Meyer; Fernando C Fervenza; Winnie Lau; Adam Keenan; Gabriel Cara-Fuentes; Dingwu Shao; Aalia Akber; Veronique Fremeaux-Bacchi; Sanjeev Sethi; Carla M Nester; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2017-08-24       Impact factor: 8.860

7.  Small-molecule factor D inhibitors targeting the alternative complement pathway.

Authors:  Jürgen Maibaum; Sha-Mei Liao; Anna Vulpetti; Nils Ostermann; Stefan Randl; Simon Rüdisser; Edwige Lorthiois; Paul Erbel; Bernd Kinzel; Fabrice A Kolb; Samuel Barbieri; Julia Wagner; Corinne Durand; Kamal Fettis; Solene Dussauge; Nicola Hughes; Omar Delgado; Ulrich Hommel; Ty Gould; Aengus Mac Sweeney; Bernd Gerhartz; Frederic Cumin; Stefanie Flohr; Anna Schubart; Bruce Jaffee; Richard Harrison; Antonio Maria Risitano; Jörg Eder; Karen Anderson
Journal:  Nat Chem Biol       Date:  2016-10-24       Impact factor: 15.040

Review 8.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

Review 9.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

Review 10.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.